{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:49:31Z","timestamp":1769770171529,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["412237"],"award-info":[{"award-number":["412237"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Facult\u00e9 de M\u00e9decine et des Science de la Sant\u00e9, Universit\u00e9 de Sherbrooke"},{"DOI":"10.13039\/501100023334","name":"Foundation of Stars","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Sherbrooke"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fragile X syndrome (FXS) is the most prevalent monogenic cause of intellectual disability and autism spectrum disorder (ASD). Affected individuals have a high prevalence of hypocholesterolemia, however, the underlying mechanisms and the clinical significance remains unknown. We hypothesized that decrease in the plasma cholesterol levels is associated with an alteration of cholesterol content within the lipid rafts (LRs) which ultimately affects the clinical profile of FXS individuals. The platelets LRs were isolated by ultracentrifugation on sucrose gradient from 27 FXS and 25 healthy controls, followed by measurements of proteins, cholesterol, and gangliosides content. Autistic and adaptive behaviour of affected individuals were respectively assessed by the Social Communication Questionnaire and Adaptive Behavior Assessment System. Our results suggest a decrease in the cholesterol content of LRs in FXS individuals as compared to controls. As opposed to controls, LR cholesterol was significantly associated with plasma total cholesterol (r\u2009=\u20090.47; <jats:italic>p<\/jats:italic>\u2009=\u20090.042) in the FXS group. Furthermore, the correlation between LRs cholesterol and the clinical profile showed a significant association with autistic traits (r\u2009=\u2009\u2212\u00a00.67; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and adaptative behavior (r\u2009=\u20090.70; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). These results support the clinical significance of LR cholesterol alterations in FXS. Further studies are warranted to investigate the implication of LRs in FXS pathophysiology and ASD.<\/jats:p>","DOI":"10.1038\/s41598-022-07064-z","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:24:03Z","timestamp":1645442643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association of lipid rafts cholesterol with clinical profile in fragile X syndrome"],"prefix":"10.1038","volume":"12","author":[{"given":"Amanda","family":"Toupin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9rine","family":"Benachenhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armita","family":"Abolghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Laroui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Galarneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tham\u00e0s","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artuela","family":"\u00c7aku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"7064_CR1","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10803-016-2737-1","volume":"46","author":"JE Roberts","year":"2016","unstructured":"Roberts, J. E., McCary, L. M., Shinkareva, S. V. & Bailey, D. B. Infant development in fragile X syndrome: Cross-syndrome comparisons. J. Autism Dev. Disord. 46, 2088\u20132099 (2016).","journal-title":"J. Autism Dev. Disord."},{"key":"7064_CR2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/0092-8674(91)90283-5","volume":"67","author":"YH Fu","year":"1991","unstructured":"Fu, Y. H. et al. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 67, 1047\u20131058 (1991).","journal-title":"Cell"},{"key":"7064_CR3","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/hmg\/ddg331","volume":"12","author":"LS Chen","year":"2003","unstructured":"Chen, L. S., Tassone, F., Sahota, P. & Hagerman, P. J. The (CGG)n repeat element within the 5\u2032 untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum. Mol. Genet. 12, 3067\u20133074 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"7064_CR4","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1093\/cercor\/bhz059","volume":"29","author":"J Feuge","year":"2019","unstructured":"Feuge, J., Scharkowski, F., Michaelsen-Preusse, K. & Korte, M. FMRP Modulates activity-dependent spine plasticity by binding cofilin1 mRNA and regulating localization and local translation. Cereb. Cortex 29, 5204\u20135216 (2019).","journal-title":"Cereb. Cortex"},{"key":"7064_CR5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuron.2010.01.024","volume":"65","author":"EG Harlow","year":"2011","unstructured":"Harlow, E. G., Till, S. M., Russell, T. A., Wijetunge, L. S. & Kind, P. Critical period plasticity is disrupted in the barrel cortex of Fmr1 knockout mice. Neuron 65, 385\u2013398 (2011).","journal-title":"Neuron"},{"key":"7064_CR6","first-page":"1","volume":"9","author":"L Costa","year":"2015","unstructured":"Costa, L., Sardone, L. M., Lacivita, E., Leopoldo, M. & Ciranna, L. Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome. Front. Behav. Neurosci. 9, 1\u201311 (2015).","journal-title":"Front. Behav. Neurosci."},{"key":"7064_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01191-2","volume":"8","author":"E Aloisi","year":"2017","unstructured":"Aloisi, E. et al. Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice. Nat. Commun. 8, 1\u201314 (2017).","journal-title":"Nat. Commun."},{"key":"7064_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2019.00001","volume":"11","author":"SY Yau","year":"2019","unstructured":"Yau, S. Y., Bettio, L., Chiu, J., Chiu, C. & Christie, B. R. Fragile-X syndrome is associated with NMDA receptor hypofunction and reduced dendritic complexity in mature dentate granule cells. Front. Mol. Neurosci. 11, 1\u201310 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"7064_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuron.2008.10.004","volume":"60","author":"GJ Bassell","year":"2008","unstructured":"Bassell, G. J. & Warren, S. T. Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201\u2013214 (2008).","journal-title":"Neuron"},{"key":"7064_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-019-0650-z","volume":"9","author":"F Morin-Parent","year":"2019","unstructured":"Morin-Parent, F., Champigny, C., Lacroix, A., Corbin, F. & Lepage, J. F. Hyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome. Transl. Psychiatry 9, 1\u20139 (2019).","journal-title":"Transl. Psychiatry"},{"key":"7064_CR11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1172\/JCI0216390","volume":"110","author":"K Simons","year":"2002","unstructured":"Simons, K. & Ehehalt, R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110, 597\u2013603 (2002).","journal-title":"J. Clin. Invest."},{"key":"7064_CR12","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1113\/JP270590","volume":"594","author":"J Egawa","year":"2016","unstructured":"Egawa, J., Pearn, M. L., Lemkuil, B. P., Patel, P. M. & Head, B. P. Membrane lipid rafts and neurobiology: Age-related changes in membrane lipids and loss of neuronal function. J. Physiol. 594, 4565\u20134579 (2016).","journal-title":"J. Physiol."},{"key":"7064_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2012.00189","volume":"3","author":"DA Hicks","year":"2012","unstructured":"Hicks, D. A., Nalivaeva, N. N. & Turner, A. J. Lipid rafts and Alzheimer\u2019s disease: Protein-lipid interactions and perturbation of signaling. Front. Physiol. 3, 1\u201318 (2012).","journal-title":"Front. Physiol."},{"key":"7064_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrn2059","volume":"8","author":"JA Allen","year":"2007","unstructured":"Allen, J. A., Halverson-Tamboli, R. A. & Rasenick, M. M. Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci. 8, 128\u2013140 (2007).","journal-title":"Nat. Rev. Neurosci."},{"key":"7064_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2012.06.053","volume":"64","author":"AM Sebasti\u00e3o","year":"2013","unstructured":"Sebasti\u00e3o, A. M., Colino-Oliveira, M., Assaife-Lopes, N., Dias, R. B. & Ribeiro, J. A. Lipid rafts, synaptic transmission and plasticity: Impact in age-related neurodegenerative diseases. Neuropharmacology 64, 97\u2013107 (2013).","journal-title":"Neuropharmacology"},{"key":"7064_CR16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2018.02.022","volume":"67","author":"M D\u00edaz","year":"2018","unstructured":"D\u00edaz, M., Fabelo, N., Ferrer, I. & Mar\u00edn, R. \u201cLipid raft aging\u201d in the human frontal cortex during nonpathological aging: gender influences and potential implications in Alzheimer\u2019s disease. Neurobiol. Aging 67, 42\u201352 (2018).","journal-title":"Neurobiol. Aging"},{"key":"7064_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6606-7-1","volume":"7","author":"SE Roh","year":"2014","unstructured":"Roh, S. E., Hong, Y. H., Jang, D. C., Kim, J. & Kim, S. J. Lipid rafts serve as signaling platforms for mGlu1 receptor-mediated calcium signaling in association with caveolin. Mol. Brain 7, 1\u201312 (2014).","journal-title":"Mol. Brain"},{"key":"7064_CR18","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1523\/JNEUROSCI.23-08-03262.2003","volume":"23","author":"H Hering","year":"2003","unstructured":"Hering, H., Lin, C. C. & Sheng, M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262\u20133271 (2003).","journal-title":"J. Neurosci."},{"key":"7064_CR19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.expneurol.2008.04.019","volume":"212","author":"C Frank","year":"2008","unstructured":"Frank, C. et al. Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp. Neurol. 212, 407\u2013414 (2008).","journal-title":"Exp. Neurol."},{"key":"7064_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-019-9288-7","volume":"11","author":"EK Baker","year":"2019","unstructured":"Baker, E. K. et al. Intellectual functioning and behavioural features associated with mosaicism in fragile X syndrome. J. Neurodev. Disord. 11, 1\u201315 (2019).","journal-title":"J. Neurodev. Disord."},{"key":"7064_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0174301","volume":"12","author":"A \u00c7aku","year":"2017","unstructured":"\u00c7aku, A. et al. New insights of altered lipid profile in fragile X syndrome. PLoS ONE 12, 1\u201312 (2017).","journal-title":"PLoS ONE"},{"key":"7064_CR22","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/ATVBAHA.119.313247","volume":"39","author":"A Ben Djoudi Ouadda","year":"2019","unstructured":"Ben Djoudi Ouadda, A. et al. Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20, member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor). Arterioscler. Thromb. Vasc. Biol. 39, 1996\u20132013 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"7064_CR23","first-page":"9","volume":"112","author":"S-T Yang","year":"2017","unstructured":"Yang, S.-T., Kreutzberger, A. J. B., Lee, J., Kiessling, V. & Tamm, L. The role of cholesterol in membrane fusion. Biophys. J. 112, 9 (2017).","journal-title":"Biophys. J."},{"key":"7064_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-0965-z","volume":"18","author":"G Hussain","year":"2019","unstructured":"Hussain, G. et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 18, 1\u201312 (2019).","journal-title":"Lipids Health Dis."},{"key":"7064_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/09537104.2017.1317733","volume":"29","author":"D Pellerin","year":"2018","unstructured":"Pellerin, D., Lortie, A. & Corbin, F. Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from fragile X syndrome. Platelets 29, 113\u2013124 (2018).","journal-title":"Platelets"},{"key":"7064_CR26","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0024-3205(00)80002-8","volume":"66","author":"M Berk","year":"2000","unstructured":"Berk, M., Plein, H. & Belsham, B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci. 66, 2427\u20132432 (2000).","journal-title":"Life Sci."},{"key":"7064_CR27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1084\/jem.20071474","volume":"205","author":"CN Morrell","year":"2008","unstructured":"Morrell, C. N. et al. Glutamate mediates platelet activation through the AMPA receptor. J. Exp. Med. 205, 575\u2013584 (2008).","journal-title":"J. Exp. Med."},{"key":"7064_CR28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/1354750X.2016.1160289","volume":"21","author":"D Pellerin","year":"2016","unstructured":"Pellerin, D. et al. Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: Potential of platelet\u2019s signaling cascades as new outcome measures in clinical trials. Biomarkers 21, 497\u2013508 (2016).","journal-title":"Biomarkers"},{"key":"7064_CR29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1399-0004.2011.01798.x","volume":"82","author":"M Lessard","year":"2012","unstructured":"Lessard, M., Chouiali, A., Drouin, R., S\u00e9bire, G. & Corbin, F. Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome. Clin. Genet. 82, 472\u2013477 (2012).","journal-title":"Clin. Genet."},{"key":"7064_CR30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mad.2007.11.004","volume":"129","author":"T Casoli","year":"2008","unstructured":"Casoli, T. et al. Platelet as a physiological model to investigate apoptotic mechanisms in Alzheimer \u03b2-amyloid peptide production. Mech. Ageing Dev. 129, 154\u2013162 (2008).","journal-title":"Mech. Ageing Dev."},{"key":"7064_CR31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.32607\/20758251-2017-9-1-26-37","volume":"9","author":"AM Petrov","year":"2017","unstructured":"Petrov, A. M., Kasimov, M. R. & Zefirov, A. L. Cholesterol in the pathogenesis of Alzheimer\u2019s, Parkinson\u2019s diseases and autism: Link to synaptic dysfunction. Acta Naturae 9, 26\u201337 (2017).","journal-title":"Acta Naturae"},{"key":"7064_CR32","first-page":"139","volume":"176","author":"WJ Griffiths","year":"2018","unstructured":"Griffiths, W. J. et al. Sterols and oxysterols in plasma from Smith-Lemi-Opitz syndrome patients. Physiol. Behav. 176, 139\u2013148 (2018).","journal-title":"Physiol. Behav."},{"key":"7064_CR33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.freeradbiomed.2016.10.008","volume":"101","author":"M Doria","year":"2016","unstructured":"Doria, M., Maugest, L., Moreau, T., Lizard, G. & Vejux, A. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson\u2019s disease. Free Radic. Biol. Med. 101, 393\u2013400 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"7064_CR34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.chemphyslip.2011.04.002","volume":"164","author":"V Leoni","year":"2011","unstructured":"Leoni, V. & Caccia, C. Oxysterols as biomarkers in neurodegenerative diseases. Chem. Phys. Lipids 164, 515\u2013524 (2011).","journal-title":"Chem. Phys. Lipids"},{"key":"7064_CR35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-2010-1242","volume":"19","author":"V Mart\u00edn","year":"2010","unstructured":"Mart\u00edn, V. et al. Lipid alterations in lipid rafts from Alzheimer\u2019s disease human brain cortex. J. Alzheimer\u2019s Dis. 19, 489\u2013502 (2010).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"7064_CR36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.nutres.2010.04.002","volume":"30","author":"EK Kim","year":"2010","unstructured":"Kim, E. K., Neggers, Y. H., Shin, C. S., Kim, E. & Kim, E. M. Alterations in lipid profile of autistic boys: A case control study. Nutr. Res. 30, 255\u2013260 (2010).","journal-title":"Nutr. Res."},{"key":"7064_CR37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11064-011-0697-6","volume":"37","author":"CL Schengrund","year":"2012","unstructured":"Schengrund, C. L., Ali-Rahmani, F. & Ramer, J. C. Cholesterol, GM1, and autism. Neurochem. Res. 37, 1201\u20131207 (2012).","journal-title":"Neurochem. Res."},{"key":"7064_CR38","first-page":"213","volume":"273","author":"CN Shrimpton","year":"2004","unstructured":"Shrimpton, C. N., Gousset, K., Tablin, F. & L\u00f3pez, J. A. Isolation and analysis of platelet lipid rafts. Methods Mol. Biol. 273, 213\u2013228 (2004).","journal-title":"Methods Mol. Biol."},{"key":"7064_CR39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1189\/jlb.0703319","volume":"75","author":"A Larbi","year":"2004","unstructured":"Larbi, A. et al. Age-associated alterations in the recruitment of signal-transduction proteins to lipid rafts in human T lymphocytes. J. Leukoc. Biol. 75, 373\u2013381 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"7064_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-1759(02)00335-6","volume":"271","author":"N Blank","year":"2002","unstructured":"Blank, N. et al. A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. J. Immunol. Methods 271, 25\u201335 (2002).","journal-title":"J. Immunol. Methods"},{"key":"7064_CR41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1194\/jlr.D800037-JLR200","volume":"50","author":"DA Persaud-Sawin","year":"2009","unstructured":"Persaud-Sawin, D. A., Lightcap, S. & Harry, G. J. Isolation of rafts from mouse brain tissue by a detergent-free method. J. Lipid Res. 50, 759\u2013767 (2009).","journal-title":"J. Lipid Res."},{"key":"7064_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-7-123","volume":"7","author":"HJ Motulsky","year":"2006","unstructured":"Motulsky, H. J. & Brown, R. E. Detecting outliers when fitting data with nonlinear regression\u2014A new method based on robust nonlinear regression and the false discovery rate. BMC Bioinform. 7, 1\u201320 (2006).","journal-title":"BMC Bioinform."},{"key":"7064_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WAD.0000000000000041","volume":"29","author":"L Liu","year":"2015","unstructured":"Liu, L., Zhang, K., Tan, L., Chen, Y. H. & Cao, Y. P. Alterations in cholesterol and ganglioside GM1 content of lipid rafts in platelets from patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 29, 63\u201369 (2015).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"7064_CR44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/rth2.12239","volume":"3","author":"M Padmakumar","year":"2019","unstructured":"Padmakumar, M., Van Raes, E., Van Geet, C. & Freson, K. Blood platelet research in autism spectrum disorders: In search of biomarkers. Res. Pract. Thromb. Haemost. 3, 566\u2013577 (2019).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"7064_CR45","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/aur.2183","volume":"12","author":"S Benachenhou","year":"2019","unstructured":"Benachenhou, S., Etcheverry, A., Galarneau, L., Dub\u00e9, J. & \u00c7aku, A. Implication of hypocholesterolemia in autism spectrum disorder and its associated comorbidities: A retrospective case\u2013control study. Autism Res. 12, 1860\u20131869 (2019).","journal-title":"Autism Res."},{"key":"7064_CR46","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1523\/JNEUROSCI.5824-08.2009","volume":"29","author":"A Francesconi","year":"2009","unstructured":"Francesconi, A., Kumari, R. & Zukin, R. S. Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar\/lipid raft pathway. J. Neurosci. 29, 3590\u20133602 (2009).","journal-title":"J. Neurosci."},{"key":"7064_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-69454-5","volume":"10","author":"M Korinek","year":"2020","unstructured":"Korinek, M. et al. Cholesterol modulates presynaptic and postsynaptic properties of excitatory synaptic transmission. Sci. Rep. 10, 1\u201318 (2020).","journal-title":"Sci. Rep."},{"key":"7064_CR48","first-page":"1","volume":"8","author":"H Wei","year":"2018","unstructured":"Wei, H., Malcor, J. D. M. & Harper, M. T. Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets. Sci. Rep. 8, 1\u201311 (2018).","journal-title":"Sci. Rep."},{"key":"7064_CR49","first-page":"1721","volume":"290","author":"K Simons","year":"2000","unstructured":"Simons, K. & Ikonen, E. How cells handle cholesterol. Cell Biol. 290, 1721\u20131727 (2000).","journal-title":"Cell Biol."},{"key":"7064_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.b15-00716","volume":"39","author":"SY Morita","year":"2016","unstructured":"Morita, S. Y. Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis. Biol. Pharm. Bull. 39, 1\u201324 (2016).","journal-title":"Biol. Pharm. Bull."},{"key":"7064_CR51","unstructured":"Gagn\u00e9, C. & Gaudet, D. Les Dyslipoprot\u00e9in\u00e9mies: L\u2019approche Clinique. (2007)."},{"key":"7064_CR52","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1523\/JNEUROSCI.2942-18.2019","volume":"39","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. PMP22 regulates cholesterol trafficking and ABCA1-mediated cholesterol efflux. J. Neurosci. 39, 5404\u20135418 (2019).","journal-title":"J. Neurosci."},{"key":"7064_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315037","author":"H Low","year":"2020","unstructured":"Low, H. et al. Cholesterol efflux-independent modification of lipid rafts by AIBP (Apolipoprotein A-I binding protein). Arterioscler. Thromb. Vasc. Biol. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315037 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"7064_CR54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/MOL.0000000000000596","volume":"30","author":"L Fang","year":"2019","unstructured":"Fang, L. & Miller, Y. I. Regulation of lipid rafts, angiogenesis and inflammation by AIBP. Curr. Opin. Lipidol. 30, 218\u2013223 (2019).","journal-title":"Curr. Opin. Lipidol."},{"key":"7064_CR55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1194\/jlr.TR120000658","volume":"61","author":"D Sviridov","year":"2020","unstructured":"Sviridov, D., Mukhamedova, N. & Miller, Y. I. Lipid rafts as a therapeutic target. J. Lipid Res. 61, 687\u2013695 (2020).","journal-title":"J. Lipid Res."},{"key":"7064_CR56","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bbalip.2013.04.009","volume":"1831","author":"S Els\u00f8e","year":"2013","unstructured":"Els\u00f8e, S., Christoffersen, C., Luchoomun, J., Turner, S. & Nielsen, L. B. Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1831, 1287\u20131292 (2013).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"7064_CR57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jcp.25488","volume":"232","author":"V Cartocci","year":"2017","unstructured":"Cartocci, V., Servadio, M., Trezza, V. & Pallottini, V. Can cholesterol metabolism modulation affect brain function and behavior?. J. Cell. Physiol. 232, 281\u2013286 (2017).","journal-title":"J. Cell. Physiol."},{"key":"7064_CR58","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.dsx.2015.04.004","volume":"9","author":"A Wysoki\u0144ski","year":"2015","unstructured":"Wysoki\u0144ski, A., Strzelecki, D. & K\u0142oszewska, I. Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabetes Metab. Syndr. Clin. Res. Rev. 9, 168\u2013176 (2015).","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"7064_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13813455.2020.1839500","volume":"0","author":"H Nandeesha","year":"2020","unstructured":"Nandeesha, H., Keshri, N., Rajappa, M. & Menon, V. Association of hyperglycaemia and hyperlipidaemia with cognitive dysfunction in schizophrenia spectrum disorder. Arch. Physiol. Biochem. 0, 1\u20138 (2020).","journal-title":"Arch. Physiol. Biochem."},{"key":"7064_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-5-20","volume":"5","author":"B Wolozin","year":"2007","unstructured":"Wolozin, B. et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease. BMC Med. 5, 1\u201311 (2007).","journal-title":"BMC Med."},{"key":"7064_CR61","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1002\/ajmg.a.36750","volume":"164","author":"A \u00c7aku","year":"2014","unstructured":"\u00c7aku, A., Pellerin, D., Bouvier, P., Riou, E. & Corbin, F. Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open-label study. Am. J. Med. Genet. Part A 164, 2834\u20132842 (2014).","journal-title":"Am. J. Med. Genet. Part A"},{"key":"7064_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-020-09315-4","volume":"12","author":"AJ Thurman","year":"2020","unstructured":"Thurman, A. J. et al. Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. J. Neurodev. Disord. 12, 1\u201317 (2020).","journal-title":"J. Neurodev. Disord."},{"key":"7064_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0162-20.2020","volume":"7","author":"M Muscas","year":"2020","unstructured":"Muscas, M., Seo, S. S., Louros, S. R. & Osterweil, E. K. A differential effect of lovastatin versus simvastatin in neurodevelopmental disorders. eNeuro 7, 1\u20139 (2020).","journal-title":"eNeuro"},{"key":"7064_CR64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(03)00003-5","volume":"4","author":"E Istvan","year":"2003","unstructured":"Istvan, E. Statin inhibition of HMG-CoA reductase: A 3-dimensional view. Atheroscler. Suppl. 4, 3\u20138 (2003).","journal-title":"Atheroscler. Suppl."},{"key":"7064_CR65","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1073\/pnas.94.10.5401","volume":"94","author":"TA Comery","year":"1997","unstructured":"Comery, T. A. et al. Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proc. Natl. Acad. Sci. U. S. A. 94, 5401\u20135404 (1997).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"7064_CR66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B","volume":"98","author":"SA Irwin","year":"2001","unstructured":"Irwin, S. A. et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A quantitative examination. Am. J. Med. Genet. 98, 161\u2013167 (2001).","journal-title":"Am. J. Med. Genet."},{"key":"7064_CR67","doi-asserted-by":"crossref","first-page":"36049","DOI":"10.1074\/jbc.M110.110189","volume":"285","author":"R Mahfoud","year":"2010","unstructured":"Mahfoud, R., Manis, A., Binnington, B., Ackerley, C. & Lingwood, C. A. A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins. J. Biol. Chem. 285, 36049\u201336059 (2010).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07064-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:00:38Z","timestamp":1669330838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07064-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7064"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07064-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2936"}}